---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Incidence"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Incidence. Topics: U.S. age-adjusted incidence of uveal melanoma, SEER core registries, 1975 to 2020; Age-adjusted incidence of uveal melanoma by sex; Incidence of uveal melanoma by race, ethnicity, sex, and age in 37,917 cases; Annual age-adjusted incidence of uveal melanoma by race and ethnicity; 11 further topics. 15 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/incidence"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Metastatic uveal melanoma

<a id="topic-2.2.1.2.1-1"></a>

### U.S. age-adjusted incidence of uveal melanoma, SEER core registries, 1975 to 2020

> “The overall mean age-adjusted incidence of primary uveal melanoma in the US over the 45-year period from 1975 to 2020 was 5.6 per million population (95% CI: 5.5–5.7).”
> “As previously noted, a small but statistically significant (p < 0.05) annual percentage change of 0.5% was detected in whites.”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

<a id="topic-2.2.1.2.1-2"></a>

### Age-adjusted incidence of uveal melanoma by sex

> “Males had a significantly higher age-adjusted incidence of 6.3 per million population (95% CI: 6.1–6.6) compared to females with average age-adjusted incidence of 5.0 (95% CI: 4.8–5.2).”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

<a id="topic-2.2.1.2.1-3"></a>

### Incidence of uveal melanoma by race, ethnicity, sex, and age in 37,917 cases

> “A total of 37,917 UM cases were identified, with an overall AAIR of 5.54 per million (95% CI: 5.48-5.59), showing a stable but slightly increasing trend (AAPC = 0.06).”
> “Incidence was highest in non-Hispanic whites (6.87 ppm), men (6.25 ppm), and those aged 75-79 years.”

Source: [Alfaar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40936061/)

<a id="topic-2.2.1.2.1-4"></a>

### Annual age-adjusted incidence of uveal melanoma by race and ethnicity

> “The annual age-adjusted incidence (per million population) of uveal melanoma was 0.31 (black), 0.38 (Asian), 1.67 (Hispanic), and 6.02 (non-Hispanic white).”

Source: [Hu et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16226513/)

<a id="topic-2.2.1.2.1-5"></a>

### Race of uveal melanoma cases

> “A total of 98% of cases of uveal melanoma were in the white race, with only 0.6% of reported cases in the black population, and in the remaining 1.8%, race was unknown.”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

<a id="topic-2.2.1.2.1-6"></a>

### U.S. age-adjusted incidence of uveal melanoma and sex difference, NCI PDQ summary

> “The mean age-adjusted incidence of uveal melanoma in the United States is approximately 4.3 new cases per million people, with no clear variation by latitude. The incidence is higher in men (4.9 cases per million) than in women (3.7 cases per million).”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.2.1-7"></a>

### Age at diagnosis of uveal melanoma

> “Median age at diagnosis was 63 years (range: 5–90 years).”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

> “Uveal melanoma is most often diagnosed in older individuals, with a progressively rising, age-specific incidence rate that peaks near age 70 years.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

> “UM occurs in patients of all ages; 1% of cases affect the paediatric population.”
> “Incidence increases with age, rising to >20 cases per million by the age of 70.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.2.1-8"></a>

### Estimated U.S. new cases in 2026, all eye and orbit cancer

| Site, United States, 2026 | Estimated new cases, both sexes | Male | Female |
| --- | --- | --- | --- |
| Eye and orbit | “3200” | “1720” | “1480” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

> “About 3,200 new cancers (mainly melanomas) of the eye and orbit (eye socket) (1,720 in males and 1,480 in females)”

Source: [American Cancer Society key statistics for eye cancer (2026)](https://www.cancer.org/cancer/types/eye-cancer/about/key-statistics.html)

<a id="topic-2.2.1.2.1-9"></a>

### Worldwide geographic variation in incidence

> “In a recent study, incidence that correlated with latitude was expressed as a north-to-south decreasing gradient, ranging from ≥8.0 cases per million person-years in Northern/Western Europe and Oceania, to 2.0-7.9 in North America, Eastern Europe and Southern Europe and <2.0 in South America, Asia and Africa.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.2.1-10"></a>

### SEER stage at diagnosis of uveal melanoma

| SEER stage at diagnosis, uveal melanoma | N (%) |
| --- | --- |
| Localized | “6,126 (90.9)” |
| Regional | “506 (7.5)” |
| Distant | “109 (1.6)” |

Source: [Mahendraraj et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5221652/)

<a id="topic-2.2.1.2.1-11"></a>

### Localized stage at diagnosis

> “Most tumors (81.3%) were localized at diagnosis”

Source: [Alfaar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40936061/)

<a id="topic-2.2.1.2.1-12"></a>

### Detectable metastases at diagnosis of the primary tumor

> “Of 3610 patients with uveal melanoma, 69 (1.9%; 95% CI 1.5 to 2.4) presented with clinical metastasis (stage IV).”
> “Risk of synchronous metastases increased from 0.7% (T1) to 1.5% (T2), 2.6% (T3) and 7.9% (T4).”

Source: [Garg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8961763/)

> “Systemic metastases are evident in only 2% to 3% of patients at the time of diagnosis of the primary ocular melanoma.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

> “Most UMs are localised at diagnosis, with <2% presenting with detectable metastases.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.2.1-13"></a>

### Proportion of patients who develop metastases after treatment of the primary tumor

> “Although local therapy is effective for local control in >90% of cases, up to 50% of patients will develop metastases, mainly in the liver (90%).”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

> “Unfortunately, up to 50% of patients with uveal melanoma will ultimately develop metastatic disease.”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

> “Treatment of primary uveal melanoma with radiotherapy, enucleation or other modalities achieves local control in more than 90% of patients, although 40% or more ultimately develop distant metastases, most commonly in the liver.”

Source: [Carvajal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36600005/)

<a id="topic-2.2.1.2.1-14"></a>

### Cumulative incidence of metastasis at 5 and 10 years, COMS trials

> “Seven hundred thirty-nine patients were diagnosed with at least 1 site of metastasis during follow-up after treatment for choroidal melanoma. Five- and 10-year cumulative metastasis rates were 25% (95% confidence interval, 23%-27%) and 34% (95% confidence interval, 32%-37%), respectively.”

Source: [Diener-West et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16344433/)

<a id="topic-2.2.1.2.1-15"></a>

### Risk of metastasis by AJCC stage and tumor thickness

> “The AJCC Cancer Staging Manual is an anatomy-based system; tumour diameter and thickness, ciliary body involvement and extraocular extension are factors associated with the risk of metastasis at 10 years from 5% for stage I to 40% for stage III.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

> “Small thickness UM (0-3 mm in thickness) was associated with a 5- and 10-year metastatic risk of 6% and 12%. The 5-/10-year metastatic risk of medium thickness (3.1-8 mm) and large tumors (>8 mm in thickness) was 14%/26% and 35%/49%, respectively”

Source: [Wei et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9540230/)

<a id="topic-2.2.1.2.1-16"></a>

### Annual number of new U.S. cases of metastatic uveal melanoma

No evidence found.

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
